Nippon India Pharma Fund - Direct (G) vs SBI Contra Fund - Direct (G)

Nippon India Pharma Fund - Direct (G) vs SBI Contra Fund - Direct (G)

stock1

Nippon India Pharma Fund - Direct (G)

7.4%

stock2

SBI Contra Fund - Direct (G)

-0.98%

Loading chart...

About Fund

Deutsche Bank AG

Karvy Computershare Pvt. Ltd.

Citi Bank HDFC Bank Ltd. Stock Holding Corporation of India

Computer Age Management Services Pvt. Ltd Computronics Financial Services India Ltd Datamatics Financial Software Services Ltd

Very High Risk

5000

9044.23

1.12

634.5023

January 1, 2013

1

Very High Risk

5000

47361.68

1.12

413.2908

January 1, 2013

0

14.01 %

19.35 %

7.4 %

16.78 %

12.91 %

-0.98 %

Sailesh Raj Bhan

MBA (Finance), CFA.

Mr.Bhan is an MBA with specialization in Finance and CFA. Has over 9 Yrs. of experience in Equity Securities Research & Sequeir Investment Pvt. Ltd. for 5 years and with Emkay Share & stock Broker Pvt. Ltd. for 2 years.

Dinesh Balachandran

B.Tech (IIT-B) and M.S. (MIT,USA).

He has over 11 years of experience in the industry primarily as Research Analyst. Prior to joining SBIFM, He was Research Analyst with Fidelity Investment, USA for ten years.

R Srinivasan

M.Com., MFM from University of Bombay.

Prior to joining SBI he has worked with Principal PNB AMC, Oppenheimer & Co, Indosuez WI Carr and Motilal Oswal.

Get your FAQs right